In this 340B follow-up episode, we track the rapid advancement of companion legislation during the final days of the legislative session, detailing its mandate for a comprehensive study to establish baseline data on the state’s 340B drug program. We explore the study’s expanded scope to audit both medical providers and pharmaceutical manufacturers, alongside the industry’s critical testimony regarding illegal duplicate discounts and $286 million in displaced Medicaid rebates. Tune in to understand how this four-year data collection initiative could ultimately shape the operational survival of local safety-net clinics and the future cost of commercial insurance premiums.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit ilcapitolgroup.substack.com